DYN Dyne Therapeutics, Inc.

CIK 0001818794 50 ready 8-Ks latest July 20, 2026, 7:35 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing July 20, 2026, 7:35 AM ET

Top materiality 0.90

Event mix earnings ×18 · other_material ×17 · leadership ×6

Sentiment 17 pos · 1 neg · 32 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for DYN

Highest-materiality recent filing

Dyne Therapeutics announces positive initial clinical data from ACHIEVE and DELIVER trials

January 3, 2024, 6:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

DYNE-101 in ACHIEVE trial: 19% mean splicing correction at 3.4 mg/kg at 3 months; 3.8 sec myotonia benefit at 1.8 mg/kg at 6 months.
DYNE-251 in DELIVER trial: 0.88% mean dystrophin expression at 5 mg/kg at 6 months, exceeding eteplirsen with 24-fold lower dose.

Read filing →

July 20, 2026, 7:35 AM ET regulatory materiality 0.75 positive item 8.01

FDA accepts Dyne's BLA for DYNE-251 in DMD exon 51 skipping; Priority Review granted

FDA accepted BLA for z-rostudirsen (DYNE-251) to treat Duchenne muscular dystrophy amenable to exon 51 skipping.
June 22, 2026, 4:15 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Barry E. Greene elected to Dyne Therapeutics board; receives option for 57,463 shares

Elected as Class I director effective June 22, 2026, to serve until 2027 annual meeting.
June 17, 2026, 7:35 AM ET debt materiality 0.55 neutral item 1.01 item 2.03 ◈ Debt Financings ×2◈ Material Agreements

Dyne Therapeutics expands Hercules debt facility to $400M, borrows $50M on June 16, 2026

Expanded loan facility to aggregate $400M with two new $50M tranches and increased final tranche by $25M.
June 8, 2026, 4:05 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×5

Dyne Therapeutics shareholders approve doubling of authorized shares to 400M

Shareholders elected David Lubner, Brian Posner, Jason Rhodes as Class III directors to three-year terms.
June 3, 2026, 7:35 AM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Dyne Therapeutics completes enrollment of ACHIEVE registrational cohort with 71 DM1 patients

Registrational expansion cohort (REC) enrolled 71 participants; topline data expected Q1 2027.
May 11, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Dyne Q1 net loss $120.9M; BLA for z-rostudirsen on track for Q2 2026

Net loss of $120.9M ($0.73 per share) vs $115.4M ($1.05) in Q1 2025.
March 2, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Dyne posts FY2025 net loss $446M; z-rostudirsen BLA submission on track for Q2 2026

Net loss $446.2M ($3.47/share) for FY2025 vs $317.4M ($3.37/share) in FY2024; R&D expense $398.3M.
January 12, 2026, 6:59 PM ET other material materiality 0.60 neutral item 2.02 item 7.01 item 9.01

Dyne Therapeutics reports preliminary cash of ~$1.1B as of Dec 31, 2025

Preliminary unaudited cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.
December 23, 2025, 6:59 PM ET leadership materiality 0.25 neutral item 5.02

Dyne Therapeutics elects Vikram Karnani as Class II director effective Dec 22, 2025

Vikram Karnani elected to the Board as an independent director; term expires at 2028 Annual Meeting.
December 10, 2025, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Dyne Therapeutics prices upsized $350M public offering at $18.44/share

Priced 18,980,478 shares at $18.44/share; gross proceeds $350M.
December 8, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Dyne Therapeutics: DELIVER trial meets primary endpoint; dystrophin 5.46% of normal; BLA submission Q2 2026

Primary endpoint met: muscle content-adjusted dystrophin expression 5.46% of normal (p<0.0001), replicating 7-fold increase from MAD portion.
December 8, 2025, 6:59 PM ET debt materiality 0.60 neutral item 2.03 item 1.01 ◈ Debt Financings

Dyne Therapeutics borrows $50M under amended Hercules loan; up to $125M additional available

Borrowed $50M second tranche under amended Loan and Security Agreement with Hercules Capital.
November 5, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Dyne Therapeutics Q3 net loss $108M; DMD topline data expected Dec 2025; DM1 enrollment delayed to early Q2 2026

Net loss $108.0M ($0.76/share) vs $97.1M ($0.96/share) in Q3 2024; R&D $97.2M, G&A $16.7M.
October 2, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

Dyne Therapeutics elects Brian Posner as Class III director

Brian Posner elected to Board effective Oct 1, 2025; term runs until 2026 annual meeting.
August 4, 2025, 7:59 PM ET regulatory materiality 0.85 positive item 7.01 item 8.01 item 9.01

FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne MD

FDA granted Breakthrough Therapy Designation to DYNE-251 for DMD amenable to exon 51 skipping.
July 28, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Dyne Q2 net loss $110.9M extends cash runway into Q3 2027 on $215M offering

Net loss $110.9M ($0.97/sh) vs $65.1M ($0.70) in Q2 2024; R&D expenses $99.2M.
July 1, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Dyne Therapeutics prices $200M public offering of 24.2M shares at $8.25/share

Gross proceeds of $200M; net proceeds ~$187M ($215.2M if underwriters exercise 30-day option for 3.6M additional shares).
June 30, 2025, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings

Dyne Therapeutics enters $275M loan agreement with Hercules Capital; $100M funded immediately

Initial tranche of $100M funded on June 27, 2025; additional tranches up to $175M available upon milestones and lender discretion.
June 17, 2025, 7:59 PM ET regulatory materiality 0.85 positive item 7.01 item 8.01 item 9.01

FDA Breakthrough Therapy Designation for DYNE-101 in DM1; revised Accelerated Approval path

FDA granted Breakthrough Therapy Designation to DYNE-101 for myotonic dystrophy type 1 (DM1).
June 5, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

Dyne Therapeutics shareholders elect Hurwitz, Kersten; approve say-on-pay

Edward Hurwitz elected with 62.9M votes for, 27.4M withheld; Dirk Kersten with 58.3M for, 32.0M withheld.
May 8, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Dyne Q1 net loss $115.4M ($1.05/sh); advances DM1 & DMD toward 2026-2027 approvals

Cash $677.5M; expects funding operations into H2 2026.
March 20, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change

Dyne Therapeutics appoints Erick Lucera as CFO; outgoing CFO Richard Scalzo to consult

Erick Lucera named CFO and Treasurer, effective March 31, 2025; previously CFO of Editas Medicine and AVEO Pharmaceuticals.
February 27, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Dyne Therapeutics reports FY2024 net loss $317.4M; advances DYNE-101 and DYNE-251 toward accelerated approval

FDA granted Fast Track designation for DYNE-101 in DM1; registrational expansion cohort enrollment planned mid-2025.
January 10, 2025, 6:59 PM ET other material materiality 0.85 positive item 2.02 item 7.01 item 8.01 item 9.01

Dyne reports $642M cash, positive DYNE-101 DM1 data, H1 2026 submission path

Preliminary cash, equivalents, and marketable securities ~$642M as of Dec 31, 2024 (unaudited).
November 12, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Dyne Therapeutics reports Q3 net loss $97.1M; IND cleared for DYNE-101; registrational cohort enrolling for DYNE-251

Net loss $97.1M ($0.96 per share) vs $60.2M ($0.99) in Q3 2023; R&D expenses rose to $92.8M from $55.3M.
November 12, 2024, 6:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

Dyne upsizes ATM offering from $200M to $300M; $101.2M already sold

Filed prospectus supplement to sell up to $300M common stock via ATM with Jefferies, up from $200M.
September 3, 2024, 7:59 PM ET other material materiality 0.85 positive item 5.02 item 7.01 item 8.01 item 9.01 ◈ executive_change ×2

Dyne Therapeutics initiates registrational cohorts after positive Phase 1/2 DELIVER data; leadership changes

DYNE-251 (20 mg/kg Q4W) showed mean absolute dystrophin 3.71% of normal (unadjusted), >10x eteplirsen's 0.3% (cross-trial caution).
August 12, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Dyne Q2 net loss $65.1M, cash $778.8M; ACHIEVE/DELIVER data positive

Q2 2024 net loss $65.1M ($0.70/sh) vs $64.9M ($1.08/sh) in Q2 2023.
May 24, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Dyne Therapeutics shareholders elect three Class I directors, ratify Deloitte as auditor

Carlo Incerti, M.D. elected with 61,028,245 votes for, 8,752,856 withheld, 5,235,919 broker non-votes.
May 22, 2024, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01

Dyne Therapeutics prices $325.5M public offering of 10.5M shares at $31.00 per share

Gross proceeds of $325.5M; net proceeds estimated at $305.4M ($351.4M if underwriters' option is fully exercised).
May 20, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Dyne: DYNE-101 achieves 27% splicing correction at 3 months; DYNE-251 shows 3.22% dystrophin expression in DMD

DYNE-101 5.4 mg/kg Q8W showed 27% mean splicing correction across 22-gene panel at 3 months, all participants responded.
May 2, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Dyne Therapeutics Q1 net loss $65.6M; cash $453.5M; clinical trials on track for H2 data

Net loss $65.6M ($0.81 per share) vs $44.2M ($0.78) in Q1 2023.
March 25, 2024, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01 ◈ executive_change ×3

Dyne Therapeutics appoints John Cox as President and CEO, succeeding Joshua Brumm

John Cox appointed President and CEO effective March 25, 2024; also elected Class I director.
March 5, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Dyne Therapeutics FY2023 net loss $235.9M; positive DM1/DMD data and $345M offering extend runway to 2025

Q4 net loss $66.6M ($1.09/shr) vs $38.8M ($0.74/shr) YoY; FY2023 net loss $235.9M ($3.95/shr).
January 5, 2024, 6:59 PM ET other material materiality 0.80 neutral item 1.01 item 8.01 item 9.01

Dyne Therapeutics prices $300M public offering of 17.15M shares at $17.50/share

Gross proceeds ~$300.1M from 17,150,000 shares; net proceeds ~$281.6M after discounts and expenses.
January 4, 2024, 6:59 PM ET other material materiality 0.30 neutral item 8.01

Dyne Therapeutics suspends ATM offering; had raised $92.2M from prior sales

Company notified Jefferies it suspended and terminated the ATM prospectus dated Nov 17, 2021.
January 3, 2024, 6:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

Dyne Therapeutics announces positive initial clinical data from ACHIEVE and DELIVER trials

DYNE-101 in ACHIEVE trial: 19% mean splicing correction at 3.4 mg/kg at 3 months; 3.8 sec myotonia benefit at 1.8 mg/kg at 6 months.
October 30, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Dyne reports Q3 net loss $60.2M, cash $157.8M; clinical data due Jan 2024

Cash, cash equivalents and marketable securities of $157.8M; funding expected through 2024.
August 3, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Dyne Q2 net loss $64.9M ($1.08/sh); cash $207.7M; clinical data on track for H2 2023

Net loss of $64.9M ($1.08 per share) vs $52.3M ($1.01) in Q2 2022.
May 25, 2023, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×2◈ executive_change

Dyne Therapeutics director Lawrence Klein resigns; shareholders elect new directors and ratify auditor

Dr. Lawrence Klein resigned from Dyne Therapeutics board effective May 24, 2023, citing no disagreement with the company.
May 11, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Dyne Therapeutics Q1 net loss $44.2M; on track for initial trial data H2 2023

Net loss $44.2M ($0.78/share) vs $35.6M ($0.69) in Q1 2022.
March 10, 2023, 6:59 PM ET other material materiality 0.70 positive item 7.01

Dyne Therapeutics confirms no deposits or accounts at Silicon Valley Bank

Disclosure made on March 10, 2023.
March 2, 2023, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Dyne Therapeutics reports FY2022 net loss $168.1M; cash $256M; data readouts H2 2023

Cash, cash equivalents and marketable securities $256.0M as of Dec 31, 2022; expected to fund operations through 2024.
November 3, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Dyne Therapeutics Q3 net loss $41.4M; Phase 1/2 trials for DM1 and DMD underway with data H2 2023

Net loss of $41.4M ($0.80 per share) vs $42.6M ($0.83) in Q3 2021; cash $248.1M funds operations through 2024.
September 12, 2022, 7:59 PM ET other material materiality 0.65 neutral item 8.01

Dyne doses first patient in DYNE-251 DMD trial, initiates DYNE-101 DM1 trial, defers FSHD IND

First patient dosed in Phase 1/2 DELIVER trial of DYNE-251 for DMD exon 51 skipping; registrational trial targeting ~46 patients.
August 4, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Dyne Therapeutics Q2 net loss $52.3M; advances DYNE-251 and DYNE-101 trials

Net loss of $52.3M ($1.01 per share) vs. $30.0M ($0.58) in Q2 2021; R&D expenses rose to $46.7M from $23.9M.
July 5, 2022, 7:59 PM ET regulatory materiality 0.70 positive item 8.01

FDA lifts clinical hold on Dyne's IND for DYNE-251 in Duchenne muscular dystrophy

FDA cleared IND and lifted clinical hold for DYNE-251, targeting exon 51 skipping in DMD.
June 3, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

Dyne Therapeutics shareholders elect Hurwitz and Kersten to board, ratify auditor

Edward Hurwitz elected as Class II director: 20,392,039 for, 7,406,127 withheld, 3,170,612 broker non-votes.
May 2, 2022, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Dyne Therapeutics Reports Q1 2022 Net Loss of $35.6M and Provides Clinical Milestones

Net loss for Q1 2022 was $35.6 million ($0.69 per share) vs. $25.0 million in Q1 2021.
March 10, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Dyne Therapeutics reports FY2021 net loss $149.3M; cash to H2 2024; pipeline milestones outlined

Net loss of $149.3M for 2021 ($2.93/share) vs $59.4M in 2020; R&D spend $121.3M.

Executive changes

Appointed

Barry E. Greene

Class I director

DYN · Dyne Therapeutics, Inc.

Effective: 2026-06-22
Filed: June 22, 2026, 4:15 PM ET

On June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

Appointed

Erick Lucera

Chief Financial Officer and Treasurer

DYN · Dyne Therapeutics, Inc.

Effective: 2025-03-31
Filed: March 20, 2025, 7:59 PM ET

On March 20, 2025, Dyne Therapeutics, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had appointed Erick Lucera as Chief Financial Officer and Treasurer of the Company, effective as of March 31, 2025 (the “Effective Date”).

Departed

Jonathan McNeill, M.D.

Chief Business Officer

DYN · Dyne Therapeutics, Inc.

Effective: 2024-09-03
Filed: September 3, 2024, 7:59 PM ET

Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.

Departed

Susanna High

Chief Operating Officer

DYN · Dyne Therapeutics, Inc.

Effective: 2024-10-01
Filed: September 3, 2024, 7:59 PM ET

Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.

Departed

Joshua Brumm

Chief Executive Officer

DYN · Dyne Therapeutics, Inc.

Effective: 2024-03-25
Successor: John Cox
Filed: March 25, 2024, 7:59 PM ET

succeeding Joshua Brumm

Appointed

John Cox

Class I Director

DYN · Dyne Therapeutics, Inc.

Effective: 2024-03-25
Filed: March 25, 2024, 7:59 PM ET

Mr. Cox was elected as a Class I director

Appointed

John Cox

President and Chief Executive Officer

DYN · Dyne Therapeutics, Inc.

Effective: 2024-03-25
Filed: March 25, 2024, 7:59 PM ET

had appointed John Cox as President and Chief Executive Officer of the Company succeeding Joshua Brumm

Departed

Dr. Lawrence Klein

member of the Board of Directors

DYN · Dyne Therapeutics, Inc.

Effective: 2023-05-24
Filed: May 25, 2023, 7:59 PM ET

On May 24, 2023, Dr. Lawrence Klein notified Dyne Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective immediately.

Appointed

Carlo Incerti

Director

DYN · Dyne Therapeutics, Inc.

Effective: 2022-03-02
Filed: March 3, 2022, 6:59 PM ET

On March 2, 2022, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Carlo Incerti, M.D. as a Class I director to serve on the Board until the Company’s 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

Earnings & guidance

2026-Q1 EPS reported -$0.73 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

17 positive 1 negative 32 neutral

source · DYN on sec.gov